A 2014 study by NHS Blood and Transplant indicated that over one quarter of red cells were transfused to patients with haematological conditions. For platelet components, the figure is higher. Certain diagnostic groups, such as haemoglobinopathies, myelodysplastic syndromes and some haemato-oncology patients, receive multiple transfusion episodes, either over long periods, or more intensively over shorter periods. Haematology patients account for the majority of the multi-transfused population. The risk of transfusion-transmitted infection (TTI) increases with number of donor exposures, and the consequences of TTI are often more significant in immunosuppressed individuals. Historically, use of pooled plasma products in patients with clotting disorders resulted in widespread transmission of hepatitis B virus, hepatitis C virus and human immunodeficiency virus before effective screening and viral inactivation methods were introduced.

No abstract

This real-world analysis of opportunistic testing in patients with PCDs reports a 67% seropositive response rate after the first dose, 3 rising to 89% after the second dose despite extended dosing in our present cohort. Response rates and median titres remained lower than in healthy adults. 1,5 Nearly two-thirds of those seronegative after the first dose Correspondence e22

Not available.